Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Debt: 2014-2024

Historic Total Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Dec 2024 value amounting to $20.6 million.

  • Viridian Therapeutics, Inc.\DE's Total Debt rose 1.79% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 1.79%. This contributed to the annual value of $20.6 million for FY2024, which is 1.87% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Total Debt of $20.6 million as of FY2024, which was up 1.87% from $20.2 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Total Debt registered a high of $20.6 million during FY2024, and its lowest value of $20.2 million during FY2023.
  • For the 2-year period, Viridian Therapeutics, Inc.\DE's Total Debt averaged around $20.4 million, with its median value being $20.4 million (2023).
  • Data for Viridian Therapeutics, Inc.\DE's Total Debt shows a peak YoY climbed of 1.87% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Viridian Therapeutics, Inc.\DE's Total Debt stood at $20.2 million in 2023, then grew by 1.87% to $20.6 million in 2024.